PMID: 6107674Nov 8, 1980Paper

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group

Lancet

Abstract

In a randomised double-blind multicentre clinical trial the effect of continued oral anticoagulant therapy after a myocardial infarction was assessed in a group of patients over 60 years of age. Half of the 878 patients who had been on anticoagulants ever since their primary myocardial infarction received placebos instead of the anticoagulant; the others continued anticoagulant therapy. All were followed for 2 years. The levels of hypocoagulability reached in the group on anticoagulants were such that, of the registered prothrombin times ('Thrombotest'), 72% were between 107 and 180 s. 2-year total mortality was 13.4% in the placebo group and 7.6% in the group treated with anticoagulants (p = 0.017. 2-year incidence of recurrent myocardial infarction was 15.9% in the placebo group and 5.7% in the anticoagulant treated group (p = 0.0001). The incidence of intracranial events was 5.6% in the placebo group and 3.1% in the group on anticoagulants (p = 0.18). Major haemorrhagic episodes were reported by 3 placebo patients and by 27 patients treated with anticoagulants. No fatal extracranial haemorrhages were seen. In this selected group of elderly patients, continuation of intensive and stable oral anticoagulant therapy substantiall...Continue Reading

References

Feb 1, 1979·The Journal of Pathology·M J DaviesW B Robertson
Nov 17, 1977·The New England Journal of Medicine·T C ChalmersA M Kunzler
Feb 13, 1969·The New England Journal of Medicine·R H Gifford, A R Feinstein
Apr 7, 1972·Deutsche medizinische Wochenschrift·H Braunsteiner

❮ Previous
Next ❯

Citations

Sep 1, 1990·Clinical Cardiology·D MasselJ A Cairns
Nov 1, 1992·Clinical Cardiology·P Jain, S C Vlay
May 1, 1996·Clinical Cardiology·G T AlmonyE J Topol
Mar 1, 1992·Journal of Clinical Pharmacology·M D Freedman
Jul 1, 1991·European Journal of Epidemiology·A HofmanF A van den Ouweland
Jan 1, 1983·European Journal of Clinical Pharmacology·A Leizorovicz, J P Boissel
Dec 1, 1989·Cardiovascular Drugs and Therapy·B Stein, V Fuster
Mar 1, 1988·The American Journal of Cardiology·V FusterJ H Chesebro
May 1, 1983·Progress in Cardiovascular Diseases·G J Goldman, A D Pichard
Sep 1, 1987·Progress in Cardiovascular Diseases·H F Weisman, B Healy
Oct 1, 1989·Journal of the American College of Cardiology·B SteinJ H Chesebro
Sep 1, 1991·Journal of the American College of Cardiology·J J de VreedeH J Wellens
Jul 1, 1994·Journal of the American College of Cardiology·M M BodenheimerA J Moss
May 1, 1996·Journal of the American College of Cardiology·A J AzarF R Rosendaal
Dec 24, 1997·Progress in Cardiovascular Diseases·A E Schussheim, V Fuster
May 22, 2003·Thrombosis Research·Harald Arnesen
Jul 11, 1981·Lancet·G T McInnes
Jun 14, 1986·Lancet·T W Meade
Feb 20, 1988·Lancet·J P MohrT K Tatemichi
May 18, 1999·International Journal of Cardiology·A BranziV Cervi
Mar 20, 2003·Journal of the American College of Cardiology·Sonia S Anand, Salim Yusuf
May 14, 2003·Journal of the American College of Cardiology·Jack HirshUNKNOWN American Heart Association/American College of Cardiology Foundation
Dec 1, 1986·Journal of the American College of Cardiology·C E Hjemdahl-MonsenV Fuster
Apr 3, 1998·Journal of the American College of Cardiology·A S Al-KhadraM A Konstam
Mar 29, 2001·Clinics in Geriatric Medicine·R J Beyth
Oct 31, 2001·The American Journal of Geriatric Cardiology·W S Aronow
Dec 1, 1993·Australian and New Zealand Journal of Medicine·J Saour, A Gallus
Jan 1, 1997·Journal of Clinical Pharmacology·T H Müller
May 1, 1992·European Journal of Epidemiology·F R Rosendaal
May 1, 1992·European Journal of Epidemiology·C C Kelleher
Jan 1, 1989·British Journal of Haematology·F R RosendaalE Briët

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.